Angiotensin II-Mediated left ventricular abnormalities in chronic kidney disease

Journal of Investigative Medicine

Volumn 60, Issue 5, 2012, Pages 785-791

  Raizada, Veena ^a   Hillerson, Dustin ^a   Amaram, Jaya Sheela ^a   Skipper, Betty ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

ATII; CKD; LV; RAS

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; COLLAGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE; VITAMIN D;

ADRENAL GLAND; ADRENERGIC SYSTEM; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; FIBROBLAST; HEART ARRHYTHMIA; HEART BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ANEURYSM; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE COMPLIANCE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MORTALITY; OXIDATIVE STRESS; QT INTERVAL; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RIGIDITY; VITAMIN D DEFICIENCY;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; HEART VENTRICLES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84860827629     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318250b101     Document Type: Conference Paper

References (84)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169. (Pubitemid 37337595)
2. Levin A, Stevens L, McCullough PA. Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. Postgrad Med. 2002;11:53-60. (Pubitemid 34408591)
3. London GM, Parfrey PS. Cardiac disease in chronic uremia: Pathogenesis. Advances in Renal Replacement Therapy. 1997;4:194-211. (Pubitemid 27304995)
4. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697. (Pubitemid 33126826)
5. Dostal DE, Rothblum KC, Chernin MI, et al. Intracardiac detection of angiotensinogen and renin: A localized renin-angiotensin system in neonatal rat heart. Am J Physiol. 1992;263:838-863.
6. De Mello WC. Cardiac intracrine renin angiotensin system. Part of genetic reprogramming? Regul Pept. 2006;133:10-12. (Pubitemid 41820329)
7. Baker KM, Chernin MI, Schreiber T, et al. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept. 2004;120:5-13. (Pubitemid 38726186)
8. Dostal DE, Hunt RA, Kule CE, et al. Molecular mechanisms of angiotensin II in modulating cardiac function: Intracardiac effects and signal transduction pathways. J Mol Cell Cardiol. 1997;29:2893-2902. (Pubitemid 27510756)
9. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116:85-97. (Pubitemid 47016250)
10. Neumann J, Ligtenberg G, Klein II, et al. Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568-1576. (Pubitemid 38591003)
11. Valdivielso JM, Ayus JC. Role of vitamin D receptor activators on cardiovascular risk. Kidney Int Suppl. 2008;111:S44-S49.
12. Amann K, Törnig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003;63:1296-1301. (Pubitemid 36349995)
13. Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int Suppl. 2003;84:S80-S83. (Pubitemid 36513382)
14. Jeunemaitre X, Soubrier F, Kotelevtsev YV. Molecular basis of human hypertension: Role of angiotensinogen. Cell. 1992;7:169-189.
15. Jeng JR. Left ventricular mass, carotid wall thickness and angiotensinogen gene polymorphism in patients with hypertension. Am J Hypertens. 1999;12:443-450.
16. Bonnardeaux A, Davies E, Jeunemaitre X, et al Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension.1994;24:63-69. (Pubitemid 24195405)
17. Fomicheva EV, Gukova SP, Larionova VI, et al. Gene-gene interaction in the RAS system in the predisposition to myocardial infarction in elder population of St. Petersburg (Russia). Mol Genet Metab. 2000;69:76-80. (Pubitemid 30097307)
18. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: Results of the HOPE randomized study. Am J Kidney Dis. 2003;14:641-647. (Pubitemid 36246007)
19. Volpe M, Savoia C, De Paolis P, et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol. 2002;13:S173-S178. (Pubitemid 35216020)
20. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:14-16.
21. Volpe M, Camargo MJF, Mueller FB, et al. Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension. 1990;15:318-326. (Pubitemid 20097460)
22. Volpe M, Lembo G, De Luca N, et al. Abnormal hormonal and renal responses to saline load in hypertensive patients with parental history of cardiovascular accidents. Circulation. 1991;84:92-100.
23. Jürgensen JS, Grimm R, Benz K, et al. Effects of anemia and uremia and a combination of both on cardiovascular structures. Kidney Blood Press Res. 2010;33:274-281.
24. Herzog CA, Mangrum JM, Passman R, et al. Sudden cardiac death and dialysis patients. Semin Dial. 2008;21:3000-3007.
25. Liu YW, Su CT, Huang YY, et al. Left ventricular systolic strain in chronic kidney disease and hemodialysis patients. Am J Nephrol. 2011;33:84-90.
26. Raizada V, Skipper B, Taylor RA, et al. Left ventricular diastolic function in patients on hemodialysis. J Investig Med. 2010;58:791-795.
27. Hayashi SY, Rohani M, Lindholm B, et al. Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant. 2006;21:125-132. (Pubitemid 43057120)
28. McMahon AC, Vescovo G, Libera LD, et al. Contractile dysfunction of isolated ventricular myocytes in experimental uraemia. Exp Nephrol. 1996;4:144-150. (Pubitemid 26162137)
29. McMahon AC, Naqvi RU, Hurst MJ, et al. Diastolic dysfunction and abnormality of the Na+/Ca2+ exchanger in single uremic cardiac myocytes. Kidney Int. 2006;69:846-851.
30. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl. 2005;94:S120-S127.
31. Ritz E, Gross ML, Dikow R, et al. Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int Suppl. 2005;99:S66-S70.
32. Törnig J, Amann K, Ritz E, et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol. 1996;7:667-675. (Pubitemid 27465998)
33. Schlaich MP, Klingbeil A, Hilgers K, et al. Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am Heart J. 1999;138:810-817. (Pubitemid 29523266)
34. Brilla CG. The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure. Curr Opin Cardiol. 1994;S1:2-10.
35. Li YC, Kong J. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;10:229-238. (Pubitemid 34787360)
36. Walters MR, Wicker DC, Riggle PC. 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J Mol Cell Cardiol. 1986;8:67-72. (Pubitemid 16174716)
37. O'Connell TD, Berry JE, Jarvis AK, et al. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol. 1997;272(4 Pt 2):H1751-H1758.
38. Mancuso P, Rahman A, Hershey SD, et al. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol. 2008;51:559-564.
39. Weishaar RE, Kim SN, Saunders DE, et al. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol. 1990;258(1Pt1):E134-E142. (Pubitemid 20068590)
40. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22:2465-2475. (Pubitemid 351948664)
41. Donohoe P, Hendry BM, Walgama OV, et al. An altered repolarizing potassium current in rat cardiac myocytes after subtotal nephrectomy. J Am Soc Nephrol. 2000;11:1589-1599.
42. Jeron A, Hengstenberg C, Engel S, et al. The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. Eur Heart J. 2001;22:663-668. (Pubitemid 32622426)
43. Raizada V, Skipper B, Luo W, et al. Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Kidney Int. 2005;68:1186-1189. (Pubitemid 43246435)
44. Daleau P, Turgeon J. Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes. Pflugers Arch. 1994;427:553-555. (Pubitemid 24219041)
45. Klein I. Endocrine disorders and cardiovascular disease. In: Zipes, ed. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, PA: W.B. Saunders Company; 2005:2051-2065.
46. Ogishima T, Suzuki H, Hata J, et al. Zone-specific expression of aldosterone synthase cytochrome P-450 and cytochrome P-45011 beta in rat adrenal cortex: Histochemical basis for the functional zonation. Endocrinology. 1992;130:2971-2977.
47. Aguilera G, Catt KJ. Regulation of aldosterone secretion by the renin-angiotensin system during sodium restriction in rats. Proc Natl Acad Sci U S A. 1978;75:4057-4061. (Pubitemid 8399871)
48. Young DB, Paulsen AW. Interrelated effects of aldosterone and plasma potassium on potassium excretion. Am J Physiol. 1983;244:F28-F34. (Pubitemid 13195575)
49. Fuller PJ, Funder JW. Biochemistry of mineralocorticoids. In: DeGroot L, Jameson L, Burger H, eds. Endocrinology. 4th ed. Philadelphia, PA: W.B. Saunders Company; 2001:1777-1780.
50. Tremblay A, Parker KL, Lehoux JG. Dietary potassium supplementation and sodium restriction stimulate aldosteronesynthase but not 11 beta-hydroxylase P-450 messenger ribonucleic acid accumulation in rat adrenals and require angiotensin II production. Endocrinology. 1992;130:3152-3158.
51. Menachery A, Braley LM, Kifor I, et al. Dissociation in plasma renin and adrenal ANG II and aldosterone responses to sodium restriction in rats. Am J Physiol. 1991;261(4 Pt 1):E487-E494.
52. Fallo F, Chouman M, Pagotto U, et al. Effect of captopril on aldosterone response to potassium infusion in primary aldosteronism. Mineral and Electrolyte Metabolism. 1991;17:185-189.
53. Okubo S, Njjmura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Investig. 1997;99:855-860. (Pubitemid 27123621)
54. Pratt JH. Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. J Clin Investig. 1982;70:667-672. (Pubitemid 12054593)
55. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809-820. (Pubitemid 24223231)
56. Silvestre JS, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701. (Pubitemid 29237459)
57. Slight SH, Chilakamarri VK, Nasr S, et al. Inhibition of tissue repair by spironolactone: Role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem. 1998;189:47-54. (Pubitemid 28556547)
58. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395-2401. (Pubitemid 37052388)
59. Sohn HJ, Yoo KH, Jang GY, et al. Aldosterone modulates cell proliferation and apoptosis in the neonatal rat heart. J Korean Med Sci. 2010;25:1296-1304.
60. Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:634-635.
61. Yim HE, Yoo KH, Bae IS, et al. Aldosterone regulates cellular turnover and mitogen-activated protein kinase family expression in the neonatal rat kidney. J Cell Physiol. 2009;219:724-733.
62. Dooley R, Harvey BJ, Thomas W. The regulation of cell growth and survival by aldosterone. Front Bio. 2011;16:440-457.
63. Kiyomoto H, Rafiq K, Mostofa M, et al. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci. 2008;108:399-405.
64. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin IIYinduced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670. (Pubitemid 38249465)
65. Stier CT, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97-107. (Pubitemid 34246658)
66. Habibi J, Demarco VG, Ma L, et al. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol. 2011;300:H1484-H1491.
67. Vonend O, Rump LC, Ritz E. Sympathetic overactivityVthe Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial. 2008;21:326-330.
68. Libby P, Bonow RO, Mann DL. Pathophysiology of heart failure. In: Zipes D, Libby P, Bonow RO, et al, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:542-559.
69. Locatelli F, Cavalli A, Tucci B. The growing problem of intradialytic hypertension. Nat Rev Nephrol. 2010;6:41-48.
70. Despas F, Detis N, Dumonteil N, et al. Excessive sympathetic activation in heart failure with chronic renal failure: Role of chemoreflex activation. J Hypertens. 2009;27:1849-1854.
71. Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205-209.
72. Nishimura M, Tokoro T, Nishida M, et al. Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy. Int J Cardiol. 2010;142:80-86.
73. Kanbay M, Afsar B, Goldsmith D, et al. Sudden death in hemodialysis: An update. Blood Purif. 2010;30:135-145.
74. Guyton AC, Coleman TG. Quantitative analysis of the pathophysiology of hypertension.1969. J Am Soc Nephrol. 1999;10:2248-2258.
75. Amann K, Breitbach M, Ritz E, et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018-1022.
76. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-128. (Pubitemid 43902687)
77. Antman EM. ST segment elevation myocardial infarction: Pathology, pathophysiology, and clinical features. In: Bonow RO, Mann DL, Zipes DP, et al, eds. Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. China: Elsevier Saunders; 2012:1087-1110.
78. Strawn WB, Dean RH, Ferrario CM. Novel mechanisms linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst. 2000;1:11.
79. Theuer J, Dechend R, Muller N, et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord. 2002;2:1-12.
80. Molkentin JD, Dorn GW. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001;63:391-426. (Pubitemid 32304323)
81. Yamazaki T, Komuro I, Yazaki Y. Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. J Hum Hypertens. 1999;13:S43-S47. (Pubitemid 29057655)
82. Schröder D, Heger J, Piper HM, et al. Angiotensin II stimulates apoptosis via TGF signaling in ventricular cardiomyocytes of rat. J Mol Med. 2006;84:975-983. (Pubitemid 44655875)
83. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodeling. Heart Fail Rev. 2010;16:5-12.
84. Dodge S, Beardslee M, Darrow B, et al. Effects of angiotensin II on expression of the gap junction channel protein connexin 43 in neonatal rat ventricular myocytes. J Am Coll Cardiol. 1998;32:800-807. (Pubitemid 28435272)